Cara Therapeutics Profit Margin

Cara Therapeutics (CARA) currently reports a profit margin of 1196.42% as of June 2026. That compares with -317.54% in the prior-year period — up 476.8% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Cara Therapeutics's profit margin history and peer comparisons.

Cara Therapeutics's profit margin increased from -317.54% to 1196.42% — a 476.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cara Therapeutics's profit margin of 1196.42% is higher than the Healthcare sector average of 13.89%. That is roughly 8513.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cara Therapeutics's current 1196.42% should be judged against Healthcare norms (sector average: 13.89%) and against CARA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 1196.42%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Cara Therapeutics, and consider following CARA for alerts when major investors trade the stock.